Propanc (OTCQB: PPCH) is a development-stage health care company working to advance its pipeline of new and proprietary treatments for cancer patients suffering from solid tumors toward clinical trials. The company recently issued an update on the progress of additional pending patent applications, noting that it had received a written opinion from the International Search Authority regarding a recent Patent Cooperation Treaty application filed in Australia. The majority of claims in the written opinion were considered novel and inventive, as determined by the authorized officer from the Australian Patent Office. The company’s patent application in Spain, titled “Cancer Treatment,” was updated with animal data and a second application was filed with additional claims. The company in early January was awarded a U.S. patent covering a method of treating solid tumors such as pancreatic, ovarian and colorectal cancers. The allowance is a significant milestone for Propanc as it advances its lead product, PRP, toward human studies in 2017. Propanc said it plans to file a continuation application with the U.S. Patent Office to pursue additional claims based off the initial allowed application.
To learn more, visit www.propanc.com
About Propanc
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. These products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, the company intends to target patients with limited remaining therapeutic options for the treatment of solid tumors. In the future, Propanc intends to develop its lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
